scholarly journals Psycho-Social Factors Associated with Health Outcomes in Blood and Marrow Transplant Patients

2018 ◽  
Vol 24 (3) ◽  
pp. S264-S265
Author(s):  
Yordanka N. Koleva ◽  
Lisa C. Abbrecht ◽  
Reinhold Munker ◽  
Jerrold Yeo ◽  
Chenguang Zhang ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Social Factors ◽  
Marrow Transplant ◽  
Factors Associated ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

Prognostic Indicators for Blood and Marrow Transplant Patients Admitted to an Intensive Care Unit

1998 ◽  
Vol 158 (3) ◽  
pp. 876-884 ◽  
Author(s):  
KRISTEN J. PRICE ◽  
PETER F. THALL ◽  
SUSANNAH K. KISH ◽  
VICKIE R. SHANNON ◽  
BORJE S. ANDERSSON
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Marrow Transplant ◽  
Prognostic Indicators ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

2012 ◽  
Vol 36 (1) ◽  
pp. 59-66 ◽  
Author(s):  
John L. Black ◽  
Mark R. Litzow ◽  
William J. Hogan ◽  
Dennis J. O’Kane ◽  
Denise L. Walker ◽  
...  
Keyword(s):  
Marrow Transplant ◽  
Allogeneic Blood ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

scholarly journals Aromatherapy as Symptom Management for Hematology/Oncology/Blood and Marrow Transplant Patients

2017 ◽  
Vol 23 (3) ◽  
pp. S477
Author(s):  
Kathryn A. Lochmann ◽  
Azure Grossman ◽  
Christina Ebert ◽  
Carolyn Gatton
Keyword(s):  
Symptom Management ◽  
Marrow Transplant ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

scholarly journals Informal caregiving in Hematopoietic Blood and Marrow Transplant patients

2011 ◽  
Vol 15 (5) ◽  
pp. 500-507 ◽  
Author(s):  
Liz Cooke ◽  
Marcia Grant ◽  
Deborah H. Eldredge ◽  
Richard T. Maziarz ◽  
Lillian M. Nail
Keyword(s):  
Informal Caregiving ◽  
Marrow Transplant ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

scholarly journals Screening for religious/spiritual struggle in blood and marrow transplant patients

2012 ◽  
Vol 21 (4) ◽  
pp. 993-1001 ◽  
Author(s):  
Stephen D. W. King ◽  
George Fitchett ◽  
Donna L. Berry
Keyword(s):  
Marrow Transplant ◽  
Spiritual Struggle ◽  
Transplant Patients ◽  
Blood And Marrow Transplant

Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 8515-8515 ◽  
Author(s):  
Robert F. Cornell ◽  
Parameswaran Hari ◽  
Stacey Goodman ◽  
Luciano J. Costa ◽  
Raphael Fraser ◽  
...  
Keyword(s):  
Hematopoietic Cell Transplantation ◽  
Amyloid Fibril ◽  
Marrow Transplant ◽  
Primary Objective ◽  
Karnofsky Score ◽  
Factors Associated ◽  
Blood And Marrow Transplant ◽  
Induction Group ◽  
Poor Outcomes

8515 Background: AL is a clonal plasma cell (PC) disorder causing multiorgan dysfunction from amyloid fibril deposition. While bortezomib (B) induction has been used prior to AHCT recently, AHCT without prior induction has been a common practice. The primary objective of this study was to compare outcomes of AL patients who proceeded to AHCT without induction to those receiving pre-AHCT induction with B. Methods: Outcomes of 426 systemic AL AHCT recipients between 2014-2018 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) were reviewed. Patients receiving induction with therapy other than B, AHCT occurring > 9 months after diagnosis, no documented AL end-organ involvement, myeloma-defining events and conditioning other than melphalan (MEL) monotherapy were excluded. Multivariate analysis (MVA) was conducted to identify prognostic factors associated with relapse, PFS and overall survival (OS). Results: 286 patients received B induction therapy vs 140 patients receiving no induction. Age, gender, number and type of organs involved, and AL AHCT center volume were similar between the groups. Patients receiving induction had greater PC burden compared with no induction (PC ≥ 10%, 41% vs 11%, p < 0.01). Induction was B, cyclophosphamide and dexamethasone (D) in 83% followed by B, lenalidomide and D (10%) or B+D (7%). Median follow-up was 24.9 months. At 2 years, B induction vs. no induction was associated with 13% (95% CI 10-17%) vs 22% (95% CI 15-30%) relapse risk (p = 0.03); 83% (95% CI 79-87%) vs 74% (95% CI 66-81%) PFS (p = 0.04); 93% (95% CI 90-95%) vs 94% (95% CI 89-97%) OS (p = 0.7). On MVA, the B induction group had improved PFS (HR 0.46, 95% CI 0.3-0.7, p < 0.001) with similar OS (HR 0.6, 95% CI 0.3-1.2, p = 0.1) compared with no induction. Creatinine < 2 mg/dl (HR 0.55, 95% CI 0.3-0.9, p = 0.02) and Karnofsky score ≥90 (HR 0.51, 95% CI 0.33-0.78, p < 0.01) were also associated with improved PFS. MEL dose < 180 mg/m2 was associated with inferior PFS (HR 2.17, 95% CI 1.31-3.61, p < 0.01) and OS (HR 3.6, 95% CI 1.5-8.6, p < 0.01). No deaths were seen in the first 100 days post-AHCT. At last follow-up, 32 deaths occurred, 26 (81%) due to AL. Conclusions: Compared with prior CIBMTR analyses, B induction use has increased in AL AHCT recipients and a higher PC burden was the only clinical determinant. Furthermore, B induction was associated with lower relapse and improved PFS at 2 years with no OS difference despite higher proportion of patients with > 10% PC, which has been associated with poor outcomes.

Sign in / Sign up

Export Citation Format

Share Document